The Background and Future of Quizartinib for AML

November 12, 2013
Mark J. Levis, MD, PhD

Mark J. Levis, MD, PhD, Johns Hopkins University, discusses the background and future of quizartinib for FLT3-ITD acute myeloid leukemia at the 2013 Chemotherapy Foundation Symposium, which took place from November 6-8.

Clinical Pearls

Mark J. Levis, MD, PhD, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses the background and future of quizartinib for FLT3-ITD acute myeloid leukemia at the 2013 Chemotherapy Foundation Symposium, which took place from November 6-8.

  • Quizartinib could play a crucial role in the treatment of FLT3-ITD acute myeloid leukemia
  • Quizartinib has produced many clinically meaningful responses
  • The phase IIb study will analyze 30 mg and 60 mg doses